Cerevel Therapeutics Holdings, Inc. — key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2023)

$0

Net Income/Loss (FY2023)

-$432.8M

Total Assets (FY2023)

$1.2B

Total Equity (FY2023)

$673.7M

Cash Flows from Operating Activities (FY2023)

-$342.3M

Source: Cerevel Therapeutics Holdings, Inc. 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.